UBS Group
MREO

UBS Group’s Mereo BioPharma MREO Stock Holding History

UBS Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
1,447,627
-42,501
-3% -$12.7K ﹤0.01% 6286
2026
Q1 		$492K Sell
1,490,128
-68,803
-4% -$29.5K ﹤0.01% 6100
2025
Q4 		$650K Buy
1,558,931
+588,264
+61% +$1.12M ﹤0.01% 5917
2025
Q3 		$2M Buy
970,667
+597,162
+160% +$1.1M ﹤0.01% 4953
2025
Q2 		$1.01M Sell
373,505
-558,516
-60% -$1.35M ﹤0.01% 5446
2025
Q1 		$2.1M Sell
932,021
-1,716,119
-65% -$4.85M ﹤0.01% 4665
2024
Q4 		$9.27M Buy
+2,648,140
New +$10.4M ﹤0.01% 3138
2024
Q1 		– Sell
-2,813
Closed -$6.5K – 9773
2023
Q4 		$6.5K Buy
+2,813
New +$5.38K ﹤0.01% 7698
2023
Q3 		– Sell
-2,491
Closed -$3.29K – 9787
2023
Q2 		$3.29K Sell
2,491
-93,666
-97% -$109K ﹤0.01% 7647
2023
Q1 		$68K Sell
96,157
-32,384
-25% -$29.1K ﹤0.01% 6207
2022
Q4 		$96.4K Sell
128,541
-38,964
-23% -$32K ﹤0.01% 6144
2022
Q3 		$144K Buy
167,505
+127,505
+319% +$156K ﹤0.01% 5394
2022
Q2 		$45K Buy
+40,000
New +$31K ﹤0.01% 6001
2022
Q1 		– Sell
-23,306
Closed -$37K – 10657
2021
Q4 		$37K Buy
23,306
+13,357
+134% +$26.7K ﹤0.01% 7191
2021
Q3 		$24K Buy
9,949
+9,019
+970% +$23.9K ﹤0.01% 6973
2021
Q2 		$3K Sell
930
-4,189
-82% -$14.1K ﹤0.01% 8822
2021
Q1 		$17K Buy
5,119
+480
+10% +$1.7K ﹤0.01% 7522
2020
Q4 		$17K Buy
4,639
+4,456
+2,435% +$11.2K ﹤0.01% 7061
2020
Q3 		$0 Sell
183
-782
-81% -$2.29K ﹤0.01% 8260
2020
Q2 		$2K Sell
965
-855
-47% -$1.51K ﹤0.01% 7645
2020
Q1 		$2K Sell
1,820
-5,149
-74% -$8.91K ﹤0.01% 7619
2019
Q4 		$23K Buy
6,969
+5,845
+520% +$14.9K ﹤0.01% 6793
2019
Q3 		$3K Buy
1,124
+448
+66% +$1.35K ﹤0.01% 7644
2019
Q2 		$1K Buy
+676
New +$2.96K ﹤0.01% 7723

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM

UBS Group's MREO Position: Q2 2026 in Review

UBS Group reduced its Mereo BioPharma (MREO) stake by 2.9% in Q2 2026, selling an estimated $12.7K and leaving 1,447,627 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #6286.

UBS Group first reported a position in MREO in Q2 2019 and has held it in 24 quarters since. The position peaked at $9.27M in Q4 2024. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • UBS Group held 1,447,627 shares of Mereo BioPharma worth $460K as of Q2 2026.
  • UBS Group sold 42,501 Mereo BioPharma shares in Q2 2026, an estimated $12.7K.
  • Mereo BioPharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6286 holding.
  • UBS Group first reported a position in Mereo BioPharma in Q2 2019 and has held it in 24 quarters since.
  • UBS Group's Mereo BioPharma position peaked at $9.27M in Q4 2024.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.